MedPlus Subsidiary Faces Drug License Suspensions Across Three States
MedPlus Health Services disclosed that its subsidiary Optival Health Solutions Private Limited received drug license suspension orders for three stores across Maharashtra, Telangana, and Karnataka. The suspensions, ranging from one to five days, were issued under Rule 65 of the Drugs and Cosmetics Act, 1940, with combined potential revenue losses of Rs 0.75 lacs, Rs 0.09 lacs, and Rs 0.15 lacs respectively.
*this image is generated using AI for illustrative purposes only.
MedPlus Health Services has disclosed that its subsidiary, Optival Health Solutions Private Limited, has received multiple suspension orders for drug licenses across stores in Maharashtra, Telangana, and Karnataka. The disclosures were made pursuant to Regulation 30 read with Para A Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and in accordance with relevant SEBI circulars.
Drug License Suspension Details
The regulatory actions span three separate stores across different states, each involving a suspension of the drug license under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945. The following table summarises the key details of all regulatory actions as disclosed by the company:
| Parameter: | Store 1 | Store 2 | Store 3 |
|---|---|---|---|
| Authority: | Asst. Commissioner & Licensing Authority, Food & Drug Administration, MH, Nashik, Maharashtra | Assistant Director, Drugs Control Administration, Nizamabad, Telangana | Assistant Director, Drugs Control Administration, Bidar Circle, Bidar, Karnataka |
| Nature of Action: | Suspension of Drug License for five days | Suspension of Drug License for one day | Suspension of Drug License for one day |
| Store Location: | Samta Nagar, Nashik, Maharashtra | Metpally Road Armoor, Telangana | Shivnagar Bidar, Karnataka |
| Date of Receipt of Order: | May 06, 2026 | May 08, 2026 | Not specified |
| Violation: | Under Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945 | Under Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945 | Not specified |
| Potential Revenue Loss: | Rs 0.75 lacs | Rs 0.09 lacs | Rs 0.15 lacs |
Regulatory and Financial Impact
The suspension for the Nashik store was attributed to a contravention under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945, with a potential revenue loss of Rs 0.75 lacs. The Telangana store, located at Metpally Road Armoor, received a one-day suspension order from the Assistant Director, Drugs Control Administration, Nizamabad, with the order received on May 08, 2026, and a potential revenue loss of Rs 0.09 lacs. The Karnataka store at Shivnagar Bidar similarly received a one-day suspension from the Assistant Director, Drugs Control Administration, Bidar Circle, with a potential revenue loss of Rs 0.15 lacs.
The updated disclosure was made by Manoj Kumar Srivastava, Company Secretary & Compliance Officer of MedPlus Health Services, on May 09, 2026. The details of these regulatory actions are available on the company's website at www.medplusindia.com , as well as on the websites of BSE Limited and the National Stock Exchange of India Limited.
Historical Stock Returns for Medplus Health Services
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.77% | +0.29% | +3.73% | +11.09% | +5.27% | -21.98% |
Could the pattern of drug license suspensions across multiple states trigger a broader regulatory audit of MedPlus's entire store network, potentially exposing more compliance violations?
How might repeated regulatory actions under Rule 65 affect MedPlus's ability to renew drug licenses for its Optival Health Solutions subsidiary during future licensing cycles?
Will institutional investors or analysts revise their outlook on MedPlus Health Services if the frequency of such compliance disclosures increases in the coming quarters?
17
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
